Zepbound vs Retatrutide Side Effects: A Head-to-Head Comparison for Women

What Are Zepbound and Retatrutide, and How Do They Differ?

Zepbound and retatrutide are both injectable weight-loss drugs that work partly through the GLP-1 (glucagon-like peptide-1) receptor, but they are not the same drug. Zepbound contains tirzepatide, which activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Retatrutide adds a third target: the glucagon receptor. That extra mechanism changes the side-effect risk profile in ways researchers are still working out.

Why the Mechanism Difference Matters for Women

GLP-1 agonism slows gastric emptying and reduces appetite. GIP agonism may blunt nausea relative to GLP-1 alone, which is one reason tirzepatide's GI side effects were somewhat milder in trials than semaglutide's. Glucagon receptor agonism, which retatrutide adds, increases energy expenditure and fat oxidation, but it also raises heart rate and may affect liver glucose output in ways that are not yet fully characterised in women across different hormonal states.

Women's estrogen levels modulate glucagon sensitivity throughout the menstrual cycle and drop sharply at menopause. Research published in Diabetes Care has shown that postmenopausal women have altered glucagon counter-regulation compared to premenopausal women. Whether this means postmenopausal women on retatrutide experience different glucagon-driven side effects is not yet known. The honest answer is that nobody has published that data yet.

Receptor Targets at a Glance

| Drug | GLP-1 | GIP | Glucagon | |---|---|---|---| | Zepbound (tirzepatide) | Yes | Yes | No | | Retatrutide | Yes | Yes | Yes |

Zepbound Side Effects: What the Published Trial Data Shows

Zepbound's side-effect profile comes primarily from SURMOUNT-1, a 72-week Phase 3 randomised controlled trial in adults with obesity or overweight plus at least one weight-related condition. At the 15 mg dose, participants achieved a mean body-weight loss of 20.9% versus 3.1% for placebo.

Gastrointestinal Side Effects

GI events were the most common adverse effects across all tirzepatide doses. In SURMOUNT-1, nausea occurred in approximately 31% of participants on 15 mg tirzepatide versus 10% on placebo. Vomiting affected about 16%, diarrhea about 23%, and constipation about 17% at the highest dose. The majority of these events were mild to moderate and concentrated in the first 12 to 20 weeks of dose escalation.

Tirzepatide's GI tolerability appears better than semaglutide's at comparable weight-loss magnitudes, likely because GIP co-agonism partially offsets GLP-1-driven gastric slowing. This matters practically for women: nausea is one of the top reasons women discontinue GLP-1 therapy in real-world practice.

Serious Adverse Events and Warnings

In SURMOUNT-1, serious adverse events occurred in 6.3% of the 15 mg tirzepatide group versus 4.4% on placebo. Acute pancreatitis was reported in 0.2% of tirzepatide participants. Tirzepatide carries an FDA-required boxed warning for thyroid C-cell tumors based on rodent data; the FDA prescribing information states it is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Heart Rate

Mean heart rate increased by 1 to 4 beats per minute at higher tirzepatide doses in SURMOUNT-1. That increase is smaller than what is typically seen with GLP-1-only agents.

Injection-Site Reactions and Hair Loss

Injection-site reactions occurred in about 7% of tirzepatide users. Alopecia (hair thinning) was reported as an adverse event in approximately 5.7% of tirzepatide participants in SURMOUNT-1 versus 1% on placebo. This is almost certainly telogen effluvium driven by rapid caloric restriction rather than a direct drug effect, but the distinction offers little comfort when you are losing hair. Women should know this risk is real and reversible in most cases.

Retatrutide Side Effects: What the Phase 2 Trial Shows

Retatrutide's safety data comes from Jastreboff et al., a Phase 2 trial published in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with obesity and tested doses up to 12 mg over 48 weeks. At 12 mg, participants lost a mean of 24.2% of body weight, the largest average weight loss ever reported in a Phase 2 obesity drug trial at that time.

Gastrointestinal Side Effects

GI events dominated the retatrutide side-effect picture as well. Nausea occurred in 45% of participants in the 12 mg group, compared to 15% on placebo. Vomiting was reported in 29%, diarrhea in 26%, and constipation in 24% at the highest dose. These rates are meaningfully higher than the GI rates seen with tirzepatide in SURMOUNT-1, though direct comparison across trials is difficult because the populations, doses, and follow-up periods differed.

The glucagon receptor component of retatrutide is a probable driver of the higher nausea burden. Glucagon itself can cause nausea at pharmacological doses, and layering glucagon receptor agonism onto dual GIP/GLP-1 agonism appears to amplify upper GI symptoms, particularly in the early titration phase.

Heart Rate

In the Jastreboff Phase 2 trial, mean heart rate increased by approximately 4 to 5 beats per minute in the higher-dose retatrutide groups, with some participants experiencing increases exceeding 10 bpm. This is a clinically meaningful signal, particularly for women with palpitations, arrhythmia history, or mitral valve prolapse, a condition that affects women more than men.

Serious Adverse Events

Serious adverse events occurred in approximately 10% of participants in the 12 mg retatrutide group in the Phase 2 trial. One participant in the retatrutide arm died, though investigators attributed this to a cause unrelated to study drug. Pancreatitis was not reported in the Phase 2 trial but remains a theoretical class risk.

Gallbladder Events

Rapid weight loss increases bile saturation and gallstone risk. Gallbladder-related adverse events were noted in the retatrutide trial, consistent with what is seen across GLP-1 class agents. Women are already at roughly twice the baseline risk for gallstone disease compared to men, so this is a side effect to track closely.

No Direct Head-to-Head Trial Exists. Here Is What the Gap Means for You.

No randomised trial has put Zepbound and retatrutide head-to-head. The 24.2% weight loss reported for retatrutide at 48 weeks and the 20.9% for tirzepatide at 72 weeks cannot be compared directly: the trials enrolled different populations, used different dosing schedules, and ran for different durations. Any headline claiming retatrutide is "definitively better" overstates the evidence.

To make a rational choice between these drugs right now, you and your clinician need to weigh three factors that the trial data does not resolve for individual women:

1. Availability. Zepbound is FDA-approved and commercially available. Retatrutide is not yet approved and is accessible only through clinical trials or, in some cases, compounding pharmacies (a practice the FDA has warned against for GLP-1 agents).
2. Your GI tolerance threshold. If nausea is the side effect most likely to make you stop, the available cross-trial signal suggests tirzepatide may be better tolerated.
3. Your heart rate baseline. If you have a resting heart rate above 90 bpm or a history of palpitations, the larger heart-rate signal with retatrutide warrants a cardiology conversation before starting.

Women-Specific Considerations: PCOS, Perimenopause, and Metabolic Health

PCOS and Insulin Resistance

Women with PCOS carry disproportionately high rates of insulin resistance and weight-related metabolic dysfunction. Both tirzepatide and retatrutide improve insulin sensitivity through GLP-1 and GIP receptor pathways. A 2024 meta-analysis in Fertility and Sterility examined GLP-1 receptor agonist use in PCOS and found significant improvements in fasting insulin, testosterone, and menstrual regularity. Tirzepatide's dual mechanism may offer additive benefit in the insulin-resistant PCOS phenotype, though no dedicated PCOS trial for either drug has been published.

Women with PCOS also often experience more severe GI symptoms at the start of GLP-1 therapy, possibly due to pre-existing gut motility differences. Starting at the lowest available dose and titrating slowly is especially important for this group.

Perimenopause and Postmenopause

The visceral fat redistribution that occurs during the menopausal transition drives increased cardiometabolic risk. Both drugs target visceral fat preferentially over lean mass, which is a meaningful advantage over older obesity treatments. Postmenopausal women in SURMOUNT-1 were included but their results were not reported as a separate subgroup, so we are extrapolating from mixed-age data.

Women in perimenopause should also know that GLP-1 drugs may interact with the GI symptoms of hormonal flux. Estrogen affects gastric motility, and in perimenopause those effects are erratic. Nausea from tirzepatide or retatrutide may be harder to distinguish from cycle-related or hormonal nausea during this life stage.

Menstrual Cycle Effects

No published trial for either drug has prospectively reported menstrual cycle changes as a pre-specified outcome. Anecdotally, women on GLP-1-class agents report changes in cycle length, flow, and PMS symptoms, likely secondary to weight loss and improved insulin sensitivity rather than direct drug action on the hypothalamic-pituitary-ovarian axis. If you notice significant cycle disruption after starting either drug, rule out pregnancy first.

Pregnancy, Lactation, and Contraception: Required Reading

Both tirzepatide and retatrutide are contraindicated in pregnancy. Weight loss during pregnancy is associated with fetal harm. Animal reproductive toxicity studies for tirzepatide showed adverse developmental outcomes at clinically relevant exposures, and the FDA label for Zepbound states that women should discontinue the drug at least two months before a planned pregnancy.

What This Means Practically

If you are trying to conceive, you should stop Zepbound at minimum two months before attempting pregnancy. For retatrutide, the Phase 2 trial excluded women who were or planned to become pregnant, and no human pregnancy exposure data exists. The same two-month minimum washout is a reasonable precaution based on the drug's half-life, but your clinician may advise longer.

Both drugs pass through GLP-1 receptor mechanisms that are present in the placenta. Preclinical data summarised in the FDA prescribing information show embryo-fetal toxicity in rats and rabbits at exposures overlapping human therapeutic doses.

Lactation

No human lactation data exists for tirzepatide or retatrutide. The molecular weight and receptor-binding profile suggest some transfer into breast milk is plausible. The FDA label for Zepbound advises against use during breastfeeding. Until data are available, women who are breastfeeding should not use either drug.

Contraception

Women of reproductive age using either drug should use reliable contraception. Oral contraceptive absorption may be temporarily affected during periods of rapid gastric-emptying changes with GLP-1 agents. ACOG guidance on oral contraceptive use with GLP-1 agents suggests considering a barrier method or non-oral contraceptive form (IUD, implant, injectable) during the first three months of GLP-1 therapy or any time the dose is increased.

Who Is Zepbound Right For? Who Is It Not Right For?

Zepbound Is a Strong Fit If You:

• Need an FDA-approved option with a clear insurance pathway
• Have a history of poor GI tolerance on semaglutide and want the relatively better-tolerated dual-agonist option
• Have PCOS with insulin resistance and want data-supported dual GIP/GLP-1 coverage
• Are in perimenopause or postmenopause and want the drug with the most published efficacy and safety data in your demographic

Zepbound Is Not the Right Fit If You:

• Have a personal or family history of medullary thyroid carcinoma or MEN2
• Are pregnant, trying to conceive within two months, or breastfeeding
• Have a history of acute pancreatitis or gallbladder disease (requires careful risk-benefit discussion)

Who Is Retatrutide Right For? Who Is It Not Right For?

Retatrutide May Be Worth Considering If You:

• Have not responded adequately to dual-agonist therapy (after the drug is approved)
• Are enrolled in or eligible for a Phase 3 clinical trial
• Want access to the triple-agonist mechanism and can accept a less mature safety dataset

Retatrutide Is Not the Right Fit If You:

• Need an approved drug now
• Have baseline tachycardia, arrhythmia, or MVP with palpitations
• Cannot tolerate high rates of nausea (the cross-trial signal suggests a higher GI burden at maximal doses)
• Are pregnant, trying to conceive, or breastfeeding

Practical Side-Effect Management Across Both Drugs

The strategies that reduce GI side effects from GLP-1-class agents apply to both drugs:

• Start at the lowest available dose. Titrate slowly, no faster than the label recommends.
• Eat smaller meals. Avoid high-fat, high-sugar foods that exacerbate delayed gastric emptying nausea.
• Stay hydrated. Vomiting and diarrhea cause dehydration faster in women who are also exercising.
• Take the injection on a consistent day each week. GI symptoms are often worst in the 24 to 48 hours after injection.
• If nausea persists beyond week 8, talk to your prescriber about temporarily holding the dose escalation.

For hair loss (telogen effluvium): ensure adequate protein intake (at minimum 1.2 g per kg body weight per day during active weight loss), and discuss ferritin levels with your provider. Hair loss from rapid weight loss typically peaks at three to six months and resolves without stopping the drug.

The Evidence Gap Women Deserve to Know About

Neither SURMOUNT-1 nor the Jastreboff Phase 2 retatrutide trial published sex-stratified side-effect tables. This is a fundamental problem. Women metabolise drugs differently from men: lower average body water, higher average body-fat percentage, and cyclical hormonal variation all change drug concentration-time curves. Sex-disaggregated pharmacokinetic analyses are required by the FDA as of 2016 guidance but are inconsistently published in obesity drug trials.

What this means practically: the nausea rates, heart-rate increases, and hair-loss frequencies quoted above come from mixed-sex trial populations that were roughly 65 to 70% female but did not separate outcomes by sex. A 2020 FDA analysis of sex differences in drug adverse events found women report adverse drug reactions at roughly 1.5 to 1.7 times the rate of men across drug classes. The real female-specific side-effect rates for both tirzepatide and retatrutide may differ from what the headline trial numbers show.

Ask your prescriber to walk you through the sex-disaggregated PK data if it becomes available in future publications.